Q1 2026 earnings call recap: attendance, per-cap spending and EBITDA gains, pass strategy traction, portfolio moves, and risks.

"For fiscal 2027, we anticipate revenue growth of 1% to 6% and operating profit to be flat to 4%," said (CFO Vitalone), referring to Medical-Surgical Solutions. "For fiscal 2027, we anticipate free ...

Ariel Focus Fund outperformed benchmarks with a 7.30% gain in Q1 2026 despite market volatility. Read the full analysis for ...

Ariel Focus Fund rose 7.30% in Q1 2026, led by APA Corporation and SLB Limited. Read the full analysis for more details.

"We expect full fiscal year 2026 revenue to be in the range of $860 million to $880 million and non-GAAP EPS to be in the range of $0.80 to $1," said CFO & Principal Accounting Officer Maheshwari.

Gross margin commentary shifted from Q4 2025 "gross margin of 66.9%" (with true-up benefit) to Q1 2026 "just under 65%" alongside a stated full-year gross margin midpoint increase to 65%. (CEO & ...

Versus the prior quarter, Q1 leaned more heavily into acceleration language around agentic and ATS (for example, “pipeline has grown more than 30%” and ATS now expected to grow “at least 20%”), while ...

Q1 2026 earnings call highlights: guidance cut, price-gap reset, CapEx cuts, butter exit, margin outlook and risks—read now.

Q1 2026 earnings call recap: raised 2026 guidance, enterprise backlog strength, margin headwinds, and leasing inflection outlook—read now.

Zamarro guided that "unabsorbed overhead will be a headwind of approximately $90 million" in Q2 and "negative again in the third quarter," while "price/mix should continue to be positive and step up ...

Q1 2026 earnings call recap: revenue, EPS beat, raised guidance, enrollment trends, and AI initiatives—read the key takeaways now.